DQIS — Register of Scientific Objections v29

Supplementary document to the DQIS Consolidated Framework v29. 0 (Zenodo DOI: 10. 5281/zenodo. 19855263). Register of scientific objections identified during preparation for academic validation of the DQIS framework — Distributed Quorum-Based Independent Immune Surveillance. 32 objections addressed across mathematical, biological, engineering, clinical, empirical, and structural categories. Status by objection. O1 — pᵢ empirical grounding: T-γ* and T-δ on target with existing technology; T-β pᵢ=0. 004 median (AND-gate M/E, Monte Carlo 10, 000 iterations) ; T-α v3. 0 pᵢ=0. 0003–0. 002 (triple-AND-gate, best channel in system). DOWNGRADED v25. 0 from High to Medium. O2 — Channel independence: empirically validated GSE72056; inter-M/E LTD≈0; θ=0. 17 canonical; balanced quorum eliminates mTOR hub by construction. DOWNGRADED v25. 0 from High to Medium. O3 — Population-level selective pressure: O3-A structurally mitigated by Pattern Drift Sensor; O3-B (global coordination) open as infrastructure requirement. O4 — T-ε reachability pᵢ=0. 01: histotype-dependent; already on target for HER2+/EGFR-amplified. O5 — DQIS-J paediatric procedures: resolved v14. 0 — single-dose architecture; self-sustaining threshold effect. DOWNGRADED v25. 0 to Low. O6 — T-γ* temporal criterion: RESOLVED — NFAT-like integrator, 3–4 brief contacts to threshold. O7 — CHIP clonal drift: managed — pre-infusion conditioning + cfDNA barcoding every 12–18 months + selective iC9 reset. CHIP more prevalent than originally assumed. O8 — Epigenetic transgene silencing: OPEN — SFFV+AAVS1-intron1+150bp computationally optimal; T-cell organoid validation required before Phase I. O9 — Pquorum in TME: RESOLVED v12. 0 — transit model; Pquorum ≥99. 93% all tumor phases; detection threshold N~3×10³ cells. O10 — Bulk vs single-cell correlations: RESOLVED v13. 0 — ρₛc ≤ ρbulk for inter-group pairs; θ=0. 17 is upper bound; k=3 Monte Carlo correct reference. O11 — Ci-VSP immunogenicity: resolved Phase 0 — H→Q mutation recommended before Phase I; partially open for Phase I. O12 — CDIC dormant cells: managed — T-δ and T-ε cover structurally; pregnancy contraindication for CDIC mode. O13 — HLA silencing and NK missing self: HLA-E in construct; pool 6. 7× above threshold. DOWNGRADED v25. 0 to Low. O14 — Penn Medicine data transferability to children: partially resolved — Nₛs 5–9× above threshold computationally; preclinical mouse model required before Phase I. O15 — Brain reporter gap: RESOLVED v14. 0 — Sₜm + hepatic S₂ cascade; blue urine 11–24h from brain. O16 — T-α self-activation: RESOLVED MATHEMATICALLY — triple-AND-gate v3. 0; pᵢ=0. 0003–0. 002 from literature. O17 — Tonic signaling exhaustion: RESOLVED MATHEMATICALLY — PAA ε (10y) =0. 921; doxycycline+tet-on analytically proven. O18 — θ cold tumors: RESOLVED WITH DATA — GBM θ=0. 199 (NOT cold) ; PDAC θ=1. 214 (confirmed cold) ; IPS resolves PDAC. O19 — Magenta Therapeutics closure: RESOLVED — replaced with Jasper Therapeutics (briquilimab, Phase 1b Nature Medicine 2025). O20 — Data access bottleneck: RESOLVED — datasets downloaded and analysed May 2026. O21 — Normal pancreas intrinsically cold: RESOLVED — biological explanation; IPS discriminates where θ cannot. O22 — IPS module PDAC detection: RESOLVED — 15. 5× penetrance signal; IPMN early warning 10. 1×; P (false alarm) =0. 0003; no construct modification required. O23 — Bone marrow self-attack via HSC/h-MSC depolarized profile overlap with T-γ* signature: RESOLVED v23. 0 architecturally via TASE — dual-mode CXCL12-responsive synNotch master switch (Mode A peripheral, Mode B bone marrow with anti-CD34/CD90 stemness exclusion). O24 — Piezo1 Goldilocks chronic exhaustion in stiff TME: OPEN — 5 mitigation pathways mapped, primary track (e) Forced turnover (degron tag, dual-copy, HSP70 promoter) 70-80% success. O25 — NKG2D-CAR documented in vivo toxicity (Sentman lab PMC4288483): OPEN — 5 mitigation pathways mapped, primary track (e) AND-gate with SASP discriminator (synNotch-NKG2D + IL-6/IL-8/MMP-9 multi-cytokine sensor) recovers CDIC sensitivity 70-75% with toxicity 0. 10 including melanocytes (0. 50) ; GateG (Ki-67, Phase 2+) and Sequential Verification (Phase 0/1) as resolutions. HIGH OPEN. O30 — T-ε ex vivo fratricide: RESOLVED BY ARCHITECTURE — separate GMP sub-pool expansion; procedural note only. LOW. O31 — DMI flag degradation in desmoplastic TME: PDAC tₕalf 8h vs 36h physiological; poly-cationic 4xKKKK extension restores Pquorum. MEDIUM OPEN. O32 — Sequential Verification ordered quorum: T-γ* redesignated as conditional investigative trigger; CCL22-mut recruits T-δ for focused verification within 90 min; P (FP melanocytes) reduced from 2. 5×10⁻⁴ to 7. 5×10⁻⁵. MEDIUM (resolved at protocol level for Phase 0/1). Distribution by status: 11 RESOLVED, 3 LOW, 13 MEDIUM, 4 HIGH open (O7, O8, O14, O27). O28 downgraded to MEDIUM-HIGH: afami-cel FDA Aug 2024 + lifileucel FDA Feb 2024 partially falsify structural impossibility claim. Read alongside Consolidated v29 and Addendum I v15. Not a peer-reviewed publication. Prior art deposit — CC BY 4. 0. Contact: dqis. research@proton. meRelated documents: - DQIS Consolidated Framework (main document): https: //zenodo. org/records/19877553 - Addendum I — Temporal Stratification of Tail Dependence Risk: https: //zenodo. org/records/19877810